Nav: Home

Drug identified that could reverse pulmonary arterial hypertension

August 08, 2018

Scientists at Stanley Manne Children's Research Institute at Ann & Robert H. Lurie Children's Hospital of Chicago took a major step toward developing a new treatment for pulmonary arterial hypertension (PAH), a severe lung disease with a five-year survival rate of 50 percent. They identified a drug with a positive safety profile that inhibits a gene called HIF-2α, which they discovered earlier promotes the progressive thickening of the lung artery walls - a key feature of PAH called "vascular remodeling," which leads to right-sided heart failure, the main cause of death in PAH patients. Recently, they demonstrated in three clinically-relevant animal models that inhibiting HIF-2α with a compound results in reversal of established PAH, suppression of vascular remodeling and right heart failure, and increased survival. These findings were published in the American Journal of Respiratory Critical Care Medicine.

"We are thrilled to reach this critical stage in developing the first drug for pulmonary arterial hypertension that targets the mechanisms behind disease development," says lead author Zhiyu Dai, PhD, from the Manne Research Institute at Lurie Children's, who also is a Research Assistant Professor of Pediatrics at Northwestern University Feinberg School of Medicine. "We plan to complete preclinical testing of the new drug by the end of 2018 and launch a clinical trial in 2019."

In PAH, vascular remodeling causes high blood pressure in the lung arteries, interferes with the smooth flow of blood from the heart and ultimately results in right heart damage. In severe cases, the pulmonary arteries become completely blocked, leading to right heart failure and death. Currently, there is no effective therapy to reverse vascular remodeling and inhibit right heart failure in PAH. Available treatments mainly target vasoconstriction, or contraction of the lung arteries, achieving only modest improvements in PAH morbidity and mortality.

"It is exciting to see our research progressing from the bench to the bedside," says senior author and program director Youyang Zhao, PhD, from the Manne Research Institute at Lurie Children's and Professor of Pediatrics, Medicine and Pharmacology at Northwestern University Feinberg School of Medicine. "We started with creating a unique genetically modified mouse model that is the first to mimic how pulmonary arterial hypertension develops in patients. This helped us establish the potentially therapeutic benefits of inhibiting HIF-2α and the feasibility of doing this with a compound. Now we have a promising drug that we know is safe to test in a clinical trial. We are hopeful that it can reverse vascular remodeling in patients with this devastating disease and ultimately save lives."
-end-
This research is supported in part by grants from the National Institutes of Health.

Dr. Zhao is the William G. Swartchild, Jr. Distinguished Research Professor and Director of the Program for Lung and Vascular Biology at the Manne Research Institute.

Research at Ann & Robert H. Lurie Children's Hospital of Chicago is conducted through the Stanley Manne Children's Research Institute. The Manne Research Institute is focused on improving child health, transforming pediatric medicine and ensuring healthier futures through the relentless pursuit of knowledge. Lurie Children's is ranked as one of the nation's top children's hospitals in the U.S.News & World Report. It is the pediatric training ground for Northwestern University Feinberg School of Medicine. Last year, the hospital served more than 208,000 children from 50 states and 58 countries.

Ann & Robert H. Lurie Children's Hospital of Chicago

Related Heart Failure Articles:

New hope for treating heart failure
Heart failure patients who are getting by on existing drug therapies can look forward to a far more effective medicine in the next five years or so, thanks to University of Alberta researchers.
Activated T-cells drive post-heart attack heart failure
Chronic inflammation after a heart attack can promote heart failure and death.
ICU care for COPD, heart failure and heart attack may not be better
Does a stay in the intensive care unit give patients a better chance of surviving a chronic obstructive pulmonary disease (COPD) or heart failure flare-up or even a heart attack, compared with care in another type of hospital unit?
Tissue engineering advance reduces heart failure in model of heart attack
Researchers have grown heart tissue by seeding a mix of human cells onto a 1-micron-resolution scaffold made with a 3-D printer.
Smoking may lead to heart failure by thickening the heart wall
Smokers without obvious signs of heart disease were more likely than nonsmokers and former smokers to have thickened heart walls and reduced heart pumping ability.
More Heart Failure News and Heart Failure Current Events

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Teaching For Better Humans
More than test scores or good grades — what do kids need to prepare them for the future? This hour, guest host Manoush Zomorodi and TED speakers explore how to help children grow into better humans, in and out of the classroom. Guests include educators Olympia Della Flora and Liz Kleinrock, psychologist Thomas Curran, and writer Jacqueline Woodson.
Now Playing: Science for the People

#535 Superior
Apologies for the delay getting this week's episode out! A technical glitch slowed us down, but all is once again well. This week, we look at the often troubling intertwining of science and race: its long history, its ability to persist even during periods of disrepute, and the current forms it takes as it resurfaces, leveraging the internet and nationalism to buoy itself. We speak with Angela Saini, independent journalist and author of the new book "Superior: The Return of Race Science", about where race science went and how it's coming back.